Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of CBT-101 in Subjects With Advanced Solid Tumors and c-Met Dysregulation
Phase of Trial: Phase I
Latest Information Update: 28 Dec 2017
At a glance
- Drugs CBT 101-Carlbiotech (Primary)
- Indications Gastric cancer; Oesophageal cancer; Renal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors CBT Pharmaceuticals
- 28 Sep 2017 According to a CBT Pharmaceuticals media release, first patient has been dosed.
- 24 Aug 2017 Status changed from not yet recruiting to recruiting.
- 18 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.